VEC Share PerformanceMore
|52 week high||187.50 10/09/15|
|52 week low||127.00 05/01/15|
|52 week change||39.75 (30.52%)|
|4 week volume||8,794,243 02/11/15|
Latest News« previous» nextMore
17/11/2015 - 07:51 StockMarketWire
Vectura has narrowed its H1 pretax loss to GBP5.0m, from a loss of GBP8.7m, as royalties spiked 67% higher. "Vectura is co...
17/11/2015 - 07:02 RNS
RNS Number: 8923F Vectura Group plc 17 November 2015 Vectura Group plc FLAME study shows superiority of Novartis' Ultibro Breezhaler over Seretide in reducing COPD exacerbations Ultibro Breezhaler met primary endpoint and demonstrated superiority to Seretide in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to conf...
17/11/2015 - 07:00 RNS
RNS Number: 9070F Vectura Group plc 17 November 2015 Vectura Group plc - Strong interim results driven by 67% increase in royalties - Chippenham, UK - 17 November 2015: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in the development of products for the treatment of airways-related diseases, today announces its unaudited interim results for...
02/11/2015 - 16:19 RNS
RNS Number: 2765E Vectura Group plc 02 November 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acqu...
02/11/2015 - 11:36 RNS
RNS Number: 1956E Vectura Group plc 02 November 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 2 November 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following...
30/10/2015 - 11:08 Motley Fool
Shares in pharmaceutical development company Vectura (LSE:VEC) have soared by around 10% today after it announced...
30/10/2015 - 07:27 StockMarketWire
Vectura Group said a cash milestone has been triggered by the successful achievement of a further development milestone...
30/10/2015 - 07:00 RNS
RNS Number: 9428D Vectura Group plc 30 October 2015 Vectura Group plc US FDA approves new dual combination bronchodilator Utibron Neohaler and stand-alone monotherapy Seebri Neohaler for patients with chronic obstructive pulmonary disease Utibron Neohaler (formerly QVA149;indacaterol/glycopyrrolate) demonstrated superior and sustained improv...
|Dividend yield||0 %|
Latest discussion posts More
“Vectura Group plc FLAME study shows superiority of Novartis' Ultibro? Breezhaler? over Seretide? in reducing COPD exacerbations ?Ultibro? Breezhaler? met primary ...”▼
“Hi DG great set of results today and after all these years it seems VEC are now on the edge of greatness. Not sure why the dip took place I expected a drive towards 190p. But I ...”▼
“Vectura Group plc - Strong interim results driven by 67% increase in royalties - Chippenham, UK - 17 November 2015: Vectura Group plc (LSE: VEC) ("Vectura"), ...”▼
Codes & Symbols
|Symbols||VEC, LSE:VEC, VEC.L, VEC:LN, LON:VEC, XLON:VEC|